Screening comes first
Eating-disorder specialists are calling for routine screening before patients start GLP-1 medications for weight loss, arguing that the same mechanisms that help most patients can harm a smaller group.
GLP-1 drugs mimic gut hormones that slow stomach emptying and increase feelings of fullness. In someone with a restrictive eating disorder, that added suppression can deepen malnutrition and push weight loss past safe limits. In binge-eating disorder, appetite suppression may briefly cut binges while leaving the psychological drivers untouched.
Who is at risk
Guidance from the National Eating Disorders Association says the drugs can be harmful when used outside their intended purpose, when monitoring is thin, when the prescriber lacks eating-disorder expertise, or when weight loss is motivated by weight stigma. People with active anorexia nervosa or avoidant restrictive food intake disorder should not take them, clinicians say, while bulimia and binge-eating disorder call for caution and a strong medical reason.
A 2026 study in JAMA Psychiatry highlighted the risk of people with a history of disordered eating misusing GLP-1s to sustain rapid restriction. People with active eating disorders were largely left out of the trials that led to the drugs' approval, so the evidence base for that group is thin.
Signals to watch
Clinicians writing on the topic advise asking about dieting history, purging and body image before writing a prescription, and treating a patient's unease about food as worth taking seriously. Warning signs include weight loss faster than expected, secrecy around eating, and repeated cycles of restriction followed by binges.
For binge-eating disorder, lisdexamfetamine is approved by the U.S. Food and Drug Administration, and antidepressants are sometimes used for related symptoms. Screening does not mean denying treatment, specialists say; it means matching the drug to the patient and arranging follow-up when the risk is higher.